πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11299492

JAK kinase inhibitor compounds for treatment of respiratory disease

Theravance Biopharma R&D IP, LLC Β· Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11292847

Methods for treating atopic dermatitis by administering an IL-4R inhibitor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11291659

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Fulcrum Therapeutics, Inc. Β· Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11291663

Methods of treating cancer with farnesyltransferase inhibitors

Kura Oncology, Inc. Β· Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11286307

Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11279703

Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof

APTOSE BIOSCIENCES INC. Β· Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11274123

1,2,4-oxadiazole compounds as inhibitors of CD47 signalling

Aurigene Discovery Technologies Limited Β· Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11274077

4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective

The United States of America Department of Health Β· Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11267812

KRAS G12C inhibitors

Mirati Therapeutics, Inc. Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11267845

Inhibitors of CD73-mediated immunosuppression

Arcus Biosciences, Inc. Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11267782

Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2Ξ± inhibitors

NIKANG THERAPEUTICS, INC. Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11261152

Inhibitors of the N-terminal domain of the androgen receptor

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11261197

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11261231

Methods for inhibiting HIV or HCV infection by administering TIM-3 binding inhibitors

The Regents of the University of California Β· Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11254667

Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors

The United States of America as Represented by the Secretary, Dept. of Health and Human Services Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11254669

Fused imidazo-piperidine JAK inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11254666

Compound as GLS1 inhibitor

Medshine Discovery Inc. Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11254683

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

Prelude Therapeutics, Incorporated Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11254664

Benzodiazepine derivatives as RSV inhibitors

Enanta Pharmaceuticals, Inc. Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11247985

Phenyl indole allosteric inhibitors of P97 ATPase

The Regents of the University of California Β· Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11247971

Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11248044

Methods for altering body composition by administering a GDF8 inhibitor and an Activin A i

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11246859

Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers

Biomed Valley Discoveries, Inc. Β· Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11242333

Inhibitors of plasma kallikrein

KalVista Pharmaceuticals Limited Β· Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted